Several studies have shown increased rates of hyperglycemia and diabetes in schizophrenic patients treated with olanzapine. However, the underlying mechanism is poorly understood. Glucose-dependent insulinotropic polypeptide (GIP) is known to affect insulin secretion by pancreatic b cells. Recently, a meta-analysis study reported an association between a GIP receptor (GIPR) gene polymorphism (rs10423928) and insulin secretion measured by an oral glucose tolerance test (OGTT). We assessed the influence of this GIPR gene polymorphism on glucose metabolism in 60 schizophrenic patients treated with olanzapine and 103 healthy controls. The GIPR gene polymorphism was determined using TaqMan methods. We performed repeated-measures analysis of variance (ANOVA) and one-way ANOVA for the glucose and insulin levels during OGTTs in four groups divided by the GIPR gene polymorphism and cohort (schizophrenia or control). We found significant effects of the GIPR gene and cohort on the insulin levels at 30 min. Our findings suggest that schizophrenic patients with the A allele of GIPR rs10423928 are at risk of developing hyperinsulinemia when treated with antipsychotics.
Introduction
Patients with schizophrenia have a 20% shorter lifespan than the general population and a 50% increased risk of death from medical causes. 1 Patients with schizophrenia also have an increased prevalence of cardiometabolic risk factors (for example, obesity, hyperglycemia, smoking, hypertension and lipid abnormalities) in comparison with the general population. [2] [3] [4] There is growing interest in the effects of antipsychotic treatment on metabolism, based on evidence that treatment with specific antipsychotics is associated with changes in weight, plasma lipids, insulin resistance and glucose tolerance. [5] [6] [7] [8] [9] Recent treatment guidelines for patients with schizophrenia have not recommended to use clozapine and olanzapine as first-line treatment in first-episode patients because of metabolic problems. 10 Although previous studies found that impaired glucose metabolism was detected after glucose loading in patients treated with certain atypical antipsychotics, no differences were reported in the fasting plasma glucose or the homeostasis model assessment of insulin resistance (HOMA-IR). 11 Using a 75-g oral glucose tolerance test (OGTT), some published cross-sectional metabolic studies showed higher glucose or insulin levels and higher values for insulin resistance in clozapine-and olanzapine-treated schizophrenic patients in comparison with healthy controls or patients treated with risperidone, quetiapine and other first-generation antipsychotics. [12] [13] [14] Other studies found no statistically significant impacts of antipsychotics on glucose levels, glycohemoglobin, insulin levels or insulin resistance. 15 The incretin gastrointestinal hormones affect insulin secretion by pancreatic b cells. Glucose-dependent insulinotropic polypeptide (GIP) is one of two incretin hormones that stimulate an insulin response after an oral glucose challenge. GIP is a 42-amino-acid peptide that is mainly produced by duodenal K cells in the proximal small intestine. The predominant stimulus for GIP secretion is nutrient intake, as its circulating levels are low in the fasted state and rise within minutes of food ingestion. 16 The interaction of GIP with its receptor (GIPR) on pancreatic b cells increases the cyclic adenosine monophosphate levels and intracellular calcium, which enhances exocytosis of insulin-containing granules, mostly during the later response to oral glucose (20-120 min). 17 Recently, a metaanalysis of nine genome-wide association studies found a relationship between a GIPR gene polymorphism, rs10423928 (A/T) and insulin secretion measured with an OGTT in healthy subjects. 18 The A allele in GIPR gene polymorphism rs10423928 was associated with reduced insulin secretion, which could potentially increase the risk of type 2 diabetes. 18 In studies of healthy individuals, it has been shown that Asians have a lower function of pancreatic b cells than Caucasians 19 and that the basal amount of insulin secretion in Asians is approximately half that in Caucasians. Therefore, racial differences need to be considered for analyses of glucose tolerance tests. We conducted OGTTs in Japanese schizophrenic patients treated with olanzapine and Japanese healthy subjects to test the association between the GIPR gene and the glucose and insulin levels after glucose loading.
Materials and methods

Study participants
In all, 60 patients with schizophrenia and 103 healthy control subjects participated in this study after providing written informed consent. These studies were approved by the ethics committee of the Niigata University School of Medicine. Patients aged 18-65 years were included in this study if they fulfilled the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The inclusion criteria were as follows: all patients were required to have been receiving treatment with single antipsychotics and olanzapine, with no change in the antipsychotic dose over the 3-week period before study entry; all patients were recruited among inpatients at the Niigata University Medical and Dental hospitals and psychiatric hospitals in Niigata prefecture. The healthy control subjects, whose age, sex and obesity (body mass index) were matched with the patients, were mainly recruited from the staff of our hospitals, and did not any mental illnesses. The exclusion criteria were diabetes mellitus in previous assessments using the fasting glucose level or a history of diabetes mellitus. In addition to these exclusion criteria, participants were excluded if they had a history of recognized cardiovascular and respiratory conditions with hemodynamic compromise or hypoxia, malignancy, epilepsy, endocrine disease (excluding corrected stable thyroid abnormalities), fever, dehydration, nausea, pregnancy or high-dose estrogen therapy, narcotic use, oral corticosteroid or spironolactone therapy, sedative hypnotic withdrawal or treatment with either glucose-or lipid-lowering medications. One patient was excluded from the study because the fasting glucose level was above 126 mg dl À1 . Two healthy controls were excluded from the study based on unmatched characteristics (under medications included in the exclusion criteria).
Genotyping
The GIPR gene polymorphism rs10423928 (T/A) was genotyped using a TaqMan 5 0 -exonuclease assay (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) as described previously. 20 
Assessments
Body mass index and an OGTT were included in the clinical assessment. A blood sample was taken before the OGTT, and the OGTT with a 75-g challenge was conducted in the morning at around 0700 to 0900 hours after a 12-h overnight fast in all subjects. Blood samples were collected at 30, 60, 90 and 120 min after the glucose loading during the OGTT. The blood glucose and plasma insulin concentrations were measured in each sample. The serum analyses were performed by standard methods (SRL, Tokyo, Japan). A categorical abnormality of glucose metabolism in the schizophrenia and control groups was defined as follows: impaired fasting glucose (fasting glucose of 100-125 mg dl À1 ); impaired glucose tolerance (2-h glucose level of 140-199 mg dl À1 ); or diabetes (2-h glucose level of 4200 mg dl À1 ). Insulin resistance was estimated using the HOMA-IR, which was calculated as follows: HOMA-IR ¼ fasting plasma insulin (mIU ml À1 ) Â fasting plasma glucose (mg dl À1 )/405. 11 Additional parameters were calculated according to the OGTT, namely the plasma glucose and insulin area under the curve (AUC) 0-to 2-h values.
Statistical analysis
Student's t-test, the w 2 -test or an analysis of variance (ANOVA) was used for comparisons among two or four groups according to the cohort (schizophrenia or healthy control) and genotype for the demographic data. The prevalence of a categorical abnormality in the schizophrenia and control groups was compared using the w 2 -test. Repeated-measures ANOVA was conducted to examine the main effects of time (0-120 min) and groups divided by the cohort and genotype on the changes in the glucose and insulin levels for the OGTT. The level of significance was set at Po0.05 for t-test, the w 2 -test and ANOVA. For additional analyses, we conducted one-way ANOVA for the glucose and insulin levels at each time point, HOMA-IR, AUC for glucose and AUC for insulin. On the basis of 13 independent parameters, that is, the glucose and insulin levels at each time point, HOMA-IR, AUC for glucose and AUC for insulin, we performed 13 independent statistical tests. Therefore, Po0.0038 was considered statistically significant according to Bonferroni correction for multiple comparisons. Post hoc tests were performed and the level of significance was set at Po0.008 according to the Bonferroni correction because of six times comparison among four groups. All statistical analyses were performed using the SPSS statistical software package 18.0 (SPSS, Chicago, IL, USA). Demographic and clinical background variables are presented as the mean values (SD) or number of subjects.
Results
The genotype frequencies of the GIPR gene polymorphism rs10423928 are shown in Table 1 . The genetic variation was in the Hardy-Weinberg equilibrium. The demographic data are shown in Table 2 . Age, sex, family history of diabetes, current smoking, body weight and body mass index did not differ among the four groups. Duration of medication, duration of illness, dosage of olanzapine and concomitant medication, such as anticholinergics and benzodiazepine, did not differ between the schizophrenia T/T and schizophrenia A/T þ A/A groups. The numbers and percentages of the categorical abnormalities were 39 (66.1%) for normal glucose tolerance, 6 (10.2%) for impaired fasting glucose, 12 (20.3%) for impaired glucose tolerance and 2 (3.4%) for diabetes in the schizophrenia group, and 77 (76.2%) for normal glucose tolerance, 13 (12.9%) for impaired fasting glucose, 9 (8.9%) for impaired glucose tolerance and 2 (2.0%) for diabetes in the control group. The categorical abnormalities did not differ significantly between the schizophrenia and control groups (P ¼ 0.19).
Repeated-measures ANOVA revealed that the changes in the insulin levels differed significantly among the four groups (P ¼ 0.001), whereas the changes in the glucose levels did not (P ¼ 0.122). Table 3 shows descriptive data for the glucose and insulin levels during the OGTT. There were significant differences in insulin level at 30 min (P ¼ 0.001) and AUC for insulin (P ¼ 0.001). A post hoc analysis showed that the insulin level at 30 min in the schizophrenia A/T þ A/A group was significantly higher than those in the schizophrenia T/T group (P ¼ 0.002), control T/T group (Po0.001) and control A/T þ A/A group (Po0.001). The AUC for insulin The w 2 -test was used to assess significance. The four groups were compared by one-way analysis of variance. The duration of medication, duration of illness and dosage of olanzapine were compared by Student's t-test. All values represent the mean±s.d. or number of subjects.
GIPR gene, olanzapine and insulin secretion S Ono et al in the schizophrenia A/T þ A/A group was significantly higher than those in the control T/T group (Po0.001) and control A/T þ A/A group (Po0.001). The glucose levels at each time point, HOMA-IR and AUC for glucose did not differ among the four groups.
Discussion
Our findings suggest that there may be an interaction between the rs10423928 polymorphism (A/T) of the GIPR gene and schizophrenia patients treated with olanzapine, which may influence insulin secretion after glucose loading. The schizophrenia group with the A allele of rs10423928 showed significantly higher insulin levels in the OGTT than the schizophrenia group without the A allele of rs10423928 and the control groups. These findings may make it possible for us to identify an association between the GIPR polymorphism and the early insulin levels in the OGTT, although the sample sizes were relatively small. As it is well known that GIP is released after glucose loading and that the plasma GIP concentration reach its peak level at about 30 min in the OGTT, 21 it is plausible that we found associations at the 30-min time points in the OGTT.
A recent meta-analysis of nine genome-wide association studies and replication studies using non-diabetic individuals (n ¼ 22 492) found that GIPR rs10423928 A allele carriers had decreases in their insulin secretion, insulinogenic index and ratio of insulin to glucose AUC values and a lower incretin effect. 18 Furthermore, the A allele was associated with type 2 diabetes in corroborating studies (n ¼ 35 689 cases and 89 798 controls). 18 In our study, the schizophrenia group with the GIPR rs10423928 A allele showed higher insulin levels during the OGTT, and it is difficult to explain the contradiction. However, our schizophrenia group was obviously different from the healthy control group in terms of olanzapine medication and the presence of schizophrenia. A hypothesis based on our findings is that olanzapine medication and/or schizophrenia itself in synergy with the GIPR genotype contribute to hyperinsulinemia after glucose loading.
Schizophrenia itself can lead to impaired glucose metabolism, and the lifestyle factors associated with schizophrenia include inactivity, smoking and dietary habits. 4 Previous reports on drug-naive patients with schizophrenia described lower insulin sensitivity, 22 higher prevalence of impaired glucose tolerance or higher fasting insulin levels and 2-h insulin level after glucose loading in schizophrenic patients compared with controls. 23 As it is possible that schizophrenia itself is associated with vulnerability of glucose metabolism, it will be interesting to further investigate how the GIPR gene polymorphism affects glucose metabolism in schizophrenia patients in future studies.
Previous studies have shown that olanzapine increases basal insulin release in vitro as well as gives rise to elevated fasting insulin levels in treated patients. 24, 25 Studies using glucose tolerance tests have also found impaired glucose metabolism after glucose loading in patients treated with certain atypical antipsychotics. Using a frequently sampled intravenous glucose tolerance test, Henderson et al. 26 found higher fasting insulin levels and higher insulin resistance in patients treated with olanzapine compared with patients treated with risperidone. Newcomer et al. 12 implemented a modified OGTT for patients with schizophrenia who were taking oral atypical antipsychotics, such as clozapine, olanzapine and risperidone, and concluded that olanzapine (1), (2)4(3), (2) (3), (2)4(4) Abbreviations: AUC, area under the concentration-time curve; HOMA-IR, homeostasis model assessment of insulin resistance; OGTT, oral glucose tolerance test.
One-way analysis of variance was performed for the glucose levels, insulin levels, HOMA-IR, AUC glucose and AUC insulin. A post hoc analysis was performed using the Bonferroni correction. All values represent the mean±s.d. The glucose levels are shown as mg dl À1 and the insulin levels are shown as mIU ml À1 . Significant P values are shown in bold.
GIPR gene, olanzapine and insulin secretion S Ono et al and clozapine affected glucose metabolism more than the other atypical antipsychotics. Only the olanzapine and clozapine groups had higher glucose parameters than the group of patients taking oral typical antipsychotics. 12 After replacement of oral typical antipsychotics with olanzapine, risperidone or quetiapine and 24 weeks of observation, only the olanzapine group showed an increase in the range of the AUC of glucose compared with the pre-replacement value. 13 These findings suggest that olanzapine affects glucose metabolism more than quetiapine, and that risperidone has less influence on glucose tolerance. van Winkel et al. 27 reported significant differences in the fasting and OGTT glucose levels after 3 months of treatment in patients treated with or switched to olanzapine compared with aripiprazole. In a 5-month observation of treatment with olanzapine or risperidone, the 1-h glucose and insulin levels, AUC for glucose and AUC for insulin increased from baseline in the olanzapine group, but not in the risperidone group. 28 These findings suggest that olanzapine affects glucose metabolism more than risperidone. In Asian subjects, the OGTT was used to measure the impacts of olanzapine and risperidone in comparison with healthy controls. 14 The olanzapine group had a higher AUC insulin level than the control group and there was no difference between the AUC insulin levels in the risperidone and control groups, suggesting that olanzapine affects glucose metabolism.
14 Our findings also suggest that the schizophrenia group had a higher AUC insulin level than the control group, although there were no differences in the HOMA-IR between the schizophrenia and control groups. It is possible that exploring the mechanisms of the hyperinsulinemia after glucose loading during olanzapine treatment will enable us to understand how abnormal glucose metabolism is induced by antipsychotics.
Regarding other atypical antipsychotics, clozapine has been suggested to affect glucose metabolism, and treatment with clozapine produced significant upregulation of the GIP gene in the rat striatum and small intestine in a gene expression study. 29 Therefore, it is possible that the GIP and GIPR pathways may have some roles in the abnormal glucose metabolism caused by atypical antipsychotics such as clozapine and olanzapine.
Our study has several limitations that deserve further discussion. First, as the sample size in the schizophrenia group was relatively small, we cannot exclude the possibility of a type 2 error in the association between the GIPR polymorphism and the early insulin levels in OGTT. Second, we have no clear explanation for how the GIP and GIPR pathways result in hyperinsulinemia after glucose loading in the schizophrenia group treated with olanzapine, and need to plan further studies to take accurate measurements of the plasma GIP concentrations at individual time points in the OGTT. Third, the schizophrenia patients were all inpatients and there might be uncontrolled factors such as the amount of activity or dietary intake between the patients and the healthy controls. Fourth, as we used a cross-sectional study design, we cannot exclude the possibility that some subjects in the study already had impaired glucose metabolism before olanzapine medication. Hence, further prospective studies must perform an OGTT before and after olanzapine medication. Fifth, to obtain more reliable evidence proving our hypothesis that olanzapine medication and/or schizophrenia itself in synergy with the GIPR genotype contribute to hyperinsulinemia after glucose loading, it is necessary to analyze a group of patients treated with another class of medications that do not interfere with glucose metabolism such as aripiprazole or ziprasidone. 30 Sixth, we did not measure the C-peptide levels during the OGTT in this study. Insulin secretion cannot be accurately estimated from the peripheral insulin concentrations because of the hepatic extraction. The peripheral concentrations of C-peptide are used as an index of insulin secretion because C-peptide is cosecreted with insulin in an equimolar amount, but is not extracted by the liver. Measurement of the C-peptide levels and more accurate measurements of insulin secretion based on deconvolution from the C-peptide concentrations [31] [32] [33] may be useful in future studies. Finally, although promising data from genome-wide association analyses for glucose and insulin responses in the OGTT prompted us to perform this study, those studies were conducted in European populations and the GIPR rs10423928 polymorphism is an intronic single-nucleotide polymorphism with no known function. There may be different genetic backgrounds and LD structures between European and Japanese populations, and further studies to genotype dense single nucleotide polymorphisms in the whole GIPR gene region are needed.
In this study, it was shown that schizophrenic patients with the A allele of the GIPR rs10423928 polymorphism treated with antipsychotics more easily developed hyperinsulinemia after glucose loading. Hyperinsulinemia or insulin resistance is thought to be a precursor for type 2 diabetes. However, our findings do not necessarily suggest that antipsychotic medication or this genetic polymorphism can lead to the onset of diabetes, and further studies are needed. Patients treated with antipsychotic medication for schizophrenia may need to be carefully monitored for the onset of diabetes.
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